SG001 (ENLONSTOBART) is an innovative monoclonal antibody therapeutic biological candidate developed by Sumgen. The appl
SG301 is a Class I new drug, an innovative monoclonal antibody developed by Sumgen, with hematological malignant tumors
SG301SC is a the first subcutaneous anti-CD38 monoclonal antibody therapeutic biological candidate to receive IND cleara
SG1827 is a novel recombinant human CD80 variant-Fc fusion protein that co-stimulates T cell activation.
SG2918 is a first-in-class ADC with potential of eliminating immunosuppressive cells and activating tumor immune respons
SG1906 is an innovative bi-specific antibody therapeutic biological candidate developed by CNBG-Sumgen.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
